# Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector

> **NCT03351829** · NA · UNKNOWN · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 20 (estimated)

## Conditions studied

- Beta-Thalassemia

## Interventions

- **GENETIC:** Gene-modified autologous stem cells

## Key facts

- **NCT ID:** NCT03351829
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-01
- **Primary completion:** 2019-01-01
- **Final completion:** 2020-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03351829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03351829, "Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03351829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*